Justin Chakma Sells 32,814 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) insider Justin Chakma sold 32,814 shares of ARS Pharmaceuticals stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $14.00, for a total value of $459,396.00. Following the transaction, the insider now owns 203,566 shares of the company’s stock, valued at $2,849,924. The trade was a 13.88 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Justin Chakma also recently made the following trade(s):

• On Wednesday, November 27th, Justin Chakma sold 25,000 shares of ARS Pharmaceuticals stock. The shares were sold at an average price of $14.39, for a total value of $359,750.00.

ARS Pharmaceuticals Stock Up 1.1 %

Shares of NASDAQ SPRY opened at $14.53 on Friday. ARS Pharmaceuticals, Inc. has a one year low of $4.65 and a one year high of $18.51. The stock’s fifty day moving average price is $14.83 and its two-hundred day moving average price is $11.99.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on SPRY shares. William Blair upgraded ARS Pharmaceuticals to a “strong-buy” rating in a research note on Friday, August 30th. Raymond James raised shares of ARS Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and increased their price objective for the company from $18.00 to $22.00 in a research report on Tuesday, August 13th. Cantor Fitzgerald restated an “overweight” rating and set a $30.00 target price on shares of ARS Pharmaceuticals in a research note on Tuesday, October 8th. Finally, Leerink Partners upped their price target on shares of ARS Pharmaceuticals from $21.00 to $25.00 and gave the company an “outperform” rating in a research note on Friday, September 20th. Four analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $24.00.

Hedge Funds Weigh In On ARS Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the business. RA Capital Management L.P. grew its position in shares of ARS Pharmaceuticals by 14.8% during the 1st quarter. RA Capital Management L.P. now owns 10,860,977 shares of the company’s stock worth $110,999,000 after purchasing an additional 1,401,299 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of ARS Pharmaceuticals by 37.0% in the first quarter. Vanguard Group Inc. now owns 2,886,455 shares of the company’s stock valued at $29,500,000 after buying an additional 779,969 shares during the period. State Street Corp grew its position in ARS Pharmaceuticals by 10.4% during the third quarter. State Street Corp now owns 2,049,542 shares of the company’s stock worth $29,718,000 after buying an additional 193,321 shares in the last quarter. Geode Capital Management LLC increased its stake in ARS Pharmaceuticals by 3.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,234,805 shares of the company’s stock worth $17,909,000 after acquiring an additional 38,927 shares during the period. Finally, Royce & Associates LP raised its holdings in ARS Pharmaceuticals by 7.1% in the 3rd quarter. Royce & Associates LP now owns 691,455 shares of the company’s stock valued at $10,026,000 after acquiring an additional 45,755 shares in the last quarter. 68.16% of the stock is currently owned by institutional investors and hedge funds.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.